Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between inherited CYP2D6/2C19 phenotypes and anticholinergic measures in elderly patients using anticholinergic drugs.

Therapeutic drug monitoring - 1 Feb 2014

Kersten Hege, Wyller Torgeir B, Molden Espen

Abstract excerpt

BACKGROUND: To compare measures of anticholinergic activity between metabolic phenotypes of the polymorphic enzymes cytochrome P450 2D6 (CYP2D6) and CYP2C19 in the elderly patients exposed to anticholinergic agents. METHODS: Long-term nursing home patients (n = 80) with an anticholinergic drug scale (ADS) score ≥3 were recruited from 22 nursing homes in Norway. Based on pharmacogenetic analyses of mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cognition

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP2D6

Share to Norway

Share to Pharmacogenetics

Share to Radioligand Assay

Share to Statistics, Nonparametric

Source

Identifiers

PMID: 24089073
DOI: 10.1097/FTD.0b013e31829da990

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between inherited CYP2D6/2C19 phenotypes and anticholinergic measures in elderly patients using anticholinergic drugs.PMID 24089073Read ↗

Cognitive function in the context of pharmacogenetic CYP2D6 variability and anticholinergic burden in older adults - results from the ActiFE study.Semantic proximity Read ↗

Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?Semantic proximity Read ↗

Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.Semantic proximity Read ↗

Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.Semantic proximity Read ↗

Association between anticholinergic drugs and apolipoprotein E epsilon4 allele and poorer cognitive function in older cardiovascular patients: a cross-sectional study.Semantic proximity Read ↗

Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.Semantic proximity Read ↗

Detailed cognitive function and use of drugs with anticholinergic properties in older people: a community-based cross-sectional study.Semantic proximity Read ↗

Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.Semantic proximity Read ↗

Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial.Semantic proximity Read ↗

Falls: The Adverse Drug Reaction of the Elderly and the Impact of PharmacogeneticsSemantic proximity Read ↗

[Effect of anticholinergic drugs on cognitive impairment in the elderly].Semantic proximity Read ↗

pNAT and CYP2D6 gene polymorphism in epileptic patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.